– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced financial results for the three and nine months ended September 30, 2025. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., comment ...

The problem of working out exactly which sort of snake did the biting may soon be a thing of the past—and an awful lot of lives may be saved in the process https://t.co/NNi2N1ja5H ...

Core Insights - AngioDynamics, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, with CEO Jim Clemmer and CFO Stephen Trowbridge presenting [1] - The company's NanoKnife System has been recognized as one of TIME's 2025 Best Inventions, highlighting its innovative impact in medical technology [6] - AngioDynamics reported a net sales figure of $75.7 million for the first quarter of fiscal year 2026, reflecting a year-over-year growth of 26.1% in the medical technology sector [7] Company Overview - AngioDynamics is a medical technology company focused on restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life [3][6] - The company’s innovative technologies are utilized by physicians in rapidly growing healthcare markets to address unmet patient needs [3] Financial Performance - For the first quarter of fiscal year 2026, which ended on August 31, 2025, AngioDynamics achieved net sales of $75.7 million, indicating strong growth in the medical technology sector [7]

Core Viewpoint - NVE Corporation's shares have experienced a 1.5% decline following the release of its second-quarter fiscal 2026 results, despite a 9.7% increase over the past month, indicating investor optimism about future growth prospects despite current revenue challenges [1] Earnings & Revenue Performance - Total revenues for the quarter ended September 30, 2025, were $6.35 million, a 6% decrease from $6.76 million in the prior year, primarily due to a 68% drop in contract R&D revenues, partially offset by a 1% increase in product sales [2] - For the first half of fiscal 2026, total revenues decreased 8% year over year to $12.45 million, with net income down 15% to $6.89 million, or $1.42 per diluted share [3] Operating Trends & Other Key Business Metrics - Gross profit for the quarter declined 14% to $4.97 million, resulting in a gross margin of 78%, down from 86% the previous year due to a less profitable product mix and increased distributor sales [4] - Operating expenses fell 7%, driven by a 23% decrease in SG&A costs, while R&D spending rose by 3% [5] Management Commentary - The CEO highlighted a 4% sequential revenue increase driven by strong growth in distributor and non-defense sales, despite a decline in defense-related business [7] - The company is shifting focus towards medical devices, industrial automation, and robotics markets, leveraging its spintronic sensors and couplers [8] Factors Influencing Performance - Revenue decline was mainly due to cyclical weakness in contract R&D, with a 21% rise in non-defense product sales partially offsetting a 64% decline in defense sales [11] - The lower gross margin was attributed to a shift in sales mix and a 45% year-over-year increase in the cost of sales due to heightened manufacturing activity [12] Outlook - Management is optimistic about continued growth in the December quarter and the second half of fiscal 2026, citing a healthy sales pipeline and favorable tax credits [14] - The company plans to spend an additional $1-$1.5 million on capital expenditures for production expansion [14] Other Developments - The board declared a quarterly cash dividend of $1 per share, payable on November 28, 2025, and reported the completion of new manufacturing equipment installation [16]

Core Insights - Exact Sciences Corporation (EXAS) is positioned for growth due to the momentum in its Cologuard and Oncotype DX tests, with ongoing investments in innovative cancer diagnostic solutions [1][4][9] - The company has a market capitalization of $10.20 billion and an estimated long-term earnings growth rate of 30.1%, outperforming the industry average of 21% [3] - Exact Sciences aims for 15% compounded revenue growth and over 20% adjusted EBITDA margins, with expected annual savings of more than $150 million by 2026 [5][9] Growth Drivers - Cologuard's growth is supported by rescreens, care gap programs, and improved commercial execution, with a focus on making it the standard of care [4] - Oncotype DX is experiencing strong international uptake, with a significant opportunity for growth as 70% of eligible patients outside the U.S. are not currently tested [4] - The launch of new products, such as Oncodetect and Cologuard Plus, enhances the company's offerings and addresses market needs [6][7][10] Operational Challenges - The company faces macroeconomic pressures, including high-interest rates and limited access to capital markets, which could impact profitability [13] - A competitive landscape in the colorectal cancer screening market poses risks, with competitors having greater resources and capabilities [14] Financial Performance - In the past year, EXAS stock has declined by 13.6%, while the S&P 500 has risen by 18.9% [2] - The Zacks Consensus Estimate for Exact Sciences' 2025 earnings has increased by 13.8% to 33 cents, with revenues projected to reach $3.16 billion, reflecting a 14.4% increase from 2023 [15]

Medical Technology Advancements - Medical technology front may have good news for needle phobic individuals [1] Expert Suggestions - Experts have lots of suggestions for people with needle phobia [1]

Neuralink to Enable Sight for the Completely BlindElon Musk says:“Neuralink starts off as a medical company. Its initial goals are to really help people who are quadriplegic, those who have lost use of their body, and enable them to control their own computer just by thinking.I think we’ve had 8 patients thus far. All 8 loved the device and are using it every day.Next year, we will do the blindsight implant, which will enable people who are completely blind, like they’ve lost both eyes and the optic nerve.” ...

Core Insights - Integer reported Q2 FY2025 GAAP revenue of $476 million, an 11.4% increase from Q2 2024, exceeding analyst estimates by $11.63 million [1] - Adjusted EPS for the quarter was $1.55, reflecting a 19.2% year-over-year growth [1][2] - Management raised profit guidance for FY2025, indicating strong operational performance, particularly in Cardio & Vascular product lines [1] Financial Performance - GAAP revenue for Q2 2025 was $476 million, up from $428 million in Q2 2024, marking an 11.2% increase [2] - Adjusted operating income rose to $81 million, a 14.1% increase from $71 million in the previous year [2] - Adjusted EBITDA increased to $99 million, up 10.2% from $89.8 million year-over-year [2] Business Overview - Integer specializes in contract manufacturing of complex medical device components for large medical technology companies [3] - The company focuses on key product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets [4] Segment Performance - Cardio & Vascular segment saw a 24% year-on-year increase in GAAP sales, reaching $286.9 million, driven by new product launches and acquisitions [6] - Cardiac Rhythm Management & Neuromodulation experienced modest organic growth of 2.3%, aligned with management expectations [6][11] - The "Other Markets" segment reported a 37.9% decline in sales, consistent with the company's strategy to exit the portable medical market [7] Strategic Initiatives - Recent acquisitions, particularly in coating technology, are aimed at enhancing Integer's capabilities and supporting vertical integration [8] - The company plans to continue investing in manufacturing and innovation while pursuing strategic acquisitions [14][15] Guidance and Outlook - Management raised full-year 2025 profit guidance, expecting adjusted operating income between $319 million and $331 million, a potential 16% increase from 2024 [14] - Adjusted EPS guidance for FY2025 is set at $6.25–$6.51, indicating up to 23% growth [14] - Revenue outlook for FY2025 is projected at $1.85 billion–$1.88 billion, reflecting confidence in customer demand and acquisitions [14]

'They took shrapnel from my heart' – the magnets saving lives in Ukraine https://t.co/aSQ6IPPftP ...